STAAR Surgical (NASDAQ:STAA) reported second-quarter 2026 net sales of $93.5 million, up 111% year over year, while net income improved to $8.1 million from a $16.8 million loss a year earlier.
Pharvaris (NASDAQ:PHVS) reported second-quarter 2026 results with cash and cash equivalents of €318 million as of June 30, 2026, while advancing clinical programs for its oral bradykinin B2 receptor antagonist deucrictibant.
Eloxx Pharmaceuticals (NASDAQ:ELOX) reported second-quarter 2026 results after completing a public offering that generated $66 million in gross proceeds and increased cash reserves to $62 million.
Kamada (NASDAQ:KMDA) reported second-quarter 2026 revenue of $54.9 million, up 23% year-over-year, with adjusted EBITDA of $14.1 million and net income of $9.3 million.
Liquidia (NASDAQ:LQDA) reported second-quarter 2026 revenue of $171.7 million, compared with $8.8 million a year earlier, driven mainly by YUTREPIA net product sales of $170.4 million.
Annexon (NASDAQ:ANNX) reported second-quarter 2026 financial results and clinical pipeline updates, including a net loss of $55.3 million, or $0.28 per share, for the quarter ended June 30, 2026.
National Vision Holdings (NASDAQ:EYE) reported second-quarter 2026 financial results with net revenue of $498.8 million, up 2.5%, and comparable store sales growth of 3.4% for the quarter ended July 4, 2026.
Eli Lilly and Company (NYSE:LLY) filed six lawsuits against U.S. businesses accused of selling black-market retatrutide products, while the company continues efforts to report illegal sales to regulators and law enforcement.
PodcastOne (NASDAQ:PODC) reported record first-quarter fiscal 2027 revenue of $16.1 million for the quarter ended June 30, 2026, up 8% year-over-year, with adjusted EBITDA increasing to $1.6 million.
DarioHealth (NASDAQ:DRIO) reported second-quarter 2026 revenue of $5.2 million, down about 4% year over year, while gross margin improved to 61.7%.
Eli Lilly (NYSE:LLY) received U.K. approval for Foundayo on August 10 for adult weight management and insufficiently controlled type 2 diabetes.
Hims & Hers Health (NYSE:HIMS) reported second-quarter 2026 revenue of $753.2 million, up 38% from $544.8 million a year earlier.
